| Author | Sarcinelli, MIchelle Alvares | |
| Author | Silva, Thalita Martins da | |
| Author | Silva, Andressa Daniele Artico | |
| Author | Patricio, Beatriz Ferreira de Carvalho | |
| Author | Paiva, Flávia Costa Mendes de | |
| Author | Lima, Raissa Santos de | |
| Author | Silva, Manuela Leal da | |
| Author | Rocha, Helvécio Vinícius Antunes | |
| Access date | 2022-07-19T17:14:25Z | |
| Available date | 2022-07-19T17:14:25Z | |
| Document date | 2021 | |
| Citation | SARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021. | pt_BR |
| ISSN | 1773-2247 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/53868 | |
| Description | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. | |
| Language | eng | pt_BR |
| Publisher | Elsevier | pt_BR |
| Rights | open access | |
| Subject in Portuguese | SARS-CoV-2 | pt_BR |
| Subject in Portuguese | Coronavírus | pt_BR |
| Subject in Portuguese | Formulações pulmonares | pt_BR |
| Subject in Portuguese | Administração de drogas pulmonares | pt_BR |
| Subject in Portuguese | Reaproveitamento de drogas | pt_BR |
| Title | The pulmonary route as a way to drug repositioning in COVID-19 therapy | pt_BR |
| Type | Article | |
| DOI | 10.1016/j.jddst.2021.102430 | |
| Abstract | Introduction: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society’s
routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there
is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy
considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a
promising approach would be the pulmonary drug delivery.
Objective: Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing
clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary
administration.
Method: A integrative literature review was conducted between June and July 2020, by extracting the results
from Clinical Trials, PubMed, Web of Science and Science Direct databases.
Results: By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4
drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and
incentive in this field.
Conclusion: Even though the lung is a target that facilitates viral infection and replication, formulations for
pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that
the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the
appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary
delivery field. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa de Pós-Graduação em Biologia Computacional e Sistemas,. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa de Pós-Graduação em Biologia Computacional e Sistemas,. Rio de Janeiro, RJ, Brasil / Universidade Federal Do Rio de Janeiro. Instituto de Biodiversidade e Sustentabilidade (NUPEM), Macaé, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Subject | SARS-CoV-2 | pt_BR |
| Subject | Coronavirus | pt_BR |
| Subject | Pulmonary formulations | pt_BR |
| Subject | Pulmonary drug delivery | pt_BR |
| Subject | Drug repurposing | pt_BR |
